explore -WSS

explore

author：explore 2025-08-28 03:35:23 - browse：9271

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Readout LOUD podcast: ASCO preview, a Duchenne trial failure

WSS

European regulators consider appeal over Amylyx ALS drug

Researchers CRISPR chickens in bid to protect them from bird flu

A fraught question for the kids of Alzheimer’s: Is it coming for us?

With trial win, GSK could get blood cancer drug back on market

Eight reasons why you should get an updated Covid vaccine

How doctors and nurses shape Google's AI

entertainment

explore

hotspot

In age of alternative facts, a scholarly course on calling out crap

NIH documents show early flaws of $1.6 billion long Covid program

Anesthesiologist group: stop taking Ozempic before surgery

Female surgeons have lower rates of long

Hollywood unions extend contract negotiations for actors

What's changing in Medicare's open enrollment this year?

Wildfire smoke exposes gaps in outdoor worker protections

STAT Readout: Today's biotech news includes Sana and Amylyx

BioMarin wins approval for gene therapy to treat hemophilia A

Wellcome Trust names Røttingen as its new CEO

entertainment

Change Healthcare can notify patients about the breach, HHS says

Peter Marks talks Operation Warp Speed for Rare Diseases

Wellcome Trust names Røttingen as its new CEO

Female surgeons have lower rates of long

ASCO: AstraZeneca says CAR

How should state employee insurance handle Wegovy?

knowledge

entertainment

entertainment

leisure time